Fox Business - The Power to Prosper
Search Site

Gilead Sciences

Lackluster earnings so far

NRF Vice President Jonathan Gold discusses the economic impact of a full port shutdown.

Read More

  1. Dow hits all-time high of 17,000

    Stifel Nicolaus portfolio manager Chad Morganlander says the Dow hitting 17,000 shows the economy is on the mend.

  2. Oracle’s $10B bond

    FBN’s Liz MacDonald on Oracle’s $10B bond offering.

  3. Health care sector drags on the S&P

    FBN’s Liz MacDonald with an update on stocks.

  4. Second tech bubble?

    Deutsche Bank senior U.S. economist Carl Riccadonna and BMO Capital Markets chief investment strategist Brian Belski on whether we’re in the second tech bubble in 15 years.

  5. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  6. Gilead Profit Triples On Hepatitis C Drug Revenue

    Gilead Sciences Inc (NASDAQ:GILD), which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2....

  7. Gilead Beats Expectations; Sovaldi Sales Hit $2.3 Bln

    Gilead Sciences Inc. reported late Tuesday its first-quarter net income rose to $2.23 billion, or $1.33 per diluted share, from $722.2 million, or 43 cents per dilut...

  8. Rallying Ahead of Earnings

    A handful of companies due to report earnings this afternoon are rallying into the close.  Note that biotechs Gilead Sciences and Amgen are advancing the most:Rallyi...

  9. After Shaky Start, Weibo Jumps in Nasdaq Debut

    Chinese Twitter (NYSE:TWTR) clone Weibo (NASDAQ:WB) closed 19% above its U.S. initial public offering price on Thursday after slashing the offering size in an attemp...

  10. Has Momentum Investing Lost its Mojo?

    Former high flying industry sectors like biotech (NASDAQGIDS:IBB) and social media stocks (NYSEARCA:SOCL) have crashed between 14-16% over the past month. Have hot m...

  11. Markets sell off, biotech sinks

    Wall Financial Group President Michael Wall, Harris Financial Group managing partner Jamie Cox, OneStopOption’s Alan Knuckman and FBN’s Jo Ling Kent break down this week’s market action.

  12. Downgrades weigh on Aeropostale shares

    FBN’s Nicole Petallides on Aeropostale and Gilead Sciences .

  1. Outlook for earnings season

    Estimize Senior Vice President Christine Short discusses her predictions for earnings and revenue.

  2. Dow breaks through 18K for first time

    FBN’s Tracy Byrnes on the state of the U.S. markets and economy.

  3. J.C. Penny earning slip signaling a market crash?

    Belpointe Chief Strategist David Nelson explains why J.C. Penny is in trouble and whether stocks are headed for a crash.

  4. Stocks to watch: CMG, DIS

    Rosenthal Wealth Management Group President Larry Rosenthal, Spectrum Management Group Managing Partner Bob Phillips, OptionPit.com founder Mark Sebastian and FBN’s Nicole Petallides on the state of the markets.

  5. Market check: TSLA, NFLX, GILD, FB

    FBN’s Nicole Petallides with the latest on the markets.

  6. Where to find value in today’s market

    Silvant Capital Management managing director Michael Sansoterra gives insight into today’s market.

  7. Sectors seeing growth now

    Brick Investment Partners managing director Chris Thorpe and Landcolt Capital founder Todd Schoenberger discuss their outlook for the economy and markets.

‹ Prev12345Next ›
Freebase CC-BY
Source: Gilead Sciences on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL